Skip Navigation

Cardiovascular Research 2001 52(2):314-320; doi:10.1016/S0008-6363(01)00372-8
© 2001 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Takeshita, S.
Right arrow Articles by Sato, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takeshita, S.
Right arrow Articles by Sato, T.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2001, European Society of Cardiology

Angiotensin-converting enzyme inhibition improves defective angiogenesis in the ischemic limb of spontaneously hypertensive rats

Satoshi Takeshitaa,*, Hirofumi Tomiyamaa, Naoyuki Yokoyamaa, Yutaka Kawamuraa, Taiji Furukawaa, Yutaka Ishigaib, Toshiro Shibanob, Takaaki Isshikia and Tomohide Satoa

aDepartment of Medicine, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan
bNew Product Research Laboratories II, Daiichi Pharmaceutical Co. Ltd., Tokyo, Japan

* Corresponding author. Tel.: +81-3-3964-1211; fax: +81-3-5375-1308 stake{at}blue.ocn.ne.jp

Objectives: Natural angiogenesis has been shown to be impaired in spontaneously hypertensive rats (SHR). The purpose of this study was to determine whether pathological angiogenesis in the setting of tissue ischemia is also impaired in SHR, and to what extent it is modified by angiotensin-converting enzyme (ACE) inhibition. Methods: Ischemia was induced in the hindlimb of SHR by excision of the femoral artery, after which the animals were randomly assigned to receive low-dose perindopril (sub-antihypertensive, 0.2 mg/kg/day), high-dose perindopril (antihypertensive, 2.0 mg/kg/day), or vehicle for 3 weeks. Wistar–Kyoto rats (WKY) with femoral artery excision served as a control group. Results: Tissue ACE activity in SHR was significantly increased compared to WKY (49.4±6.2 vs. 34.0±14.2 IU/mg, P<0.01). Administration of perindopril significantly reduced ACE activity in SHR (low dose: 12.4±2.3; high dose: 11.0±2.1 IU/mg, P<0.005). Angiogenesis of the ischemic limb muscles was significantly impaired at 4 weeks in SHR versus WKY as indicated by the lower capillary density in the former (364.5±43.0 vs. 463.8±63.0/mm2, P<0.05) as well as the reduced hindlimb perfusion assessed by laser Doppler imaging (0.86±0.08 vs. 1.03±0.09, P<0.05). Administration of perindopril significantly augmented both the capillary density (low dose: 494.3±69.8; high dose: 543.9±76.9/mm2, P<0.005) and the limb perfusion (low dose: 1.06±0.15; high dose: 1.05±0.12, P<0.05) of the ischemic limb in SHR. Conclusions: These findings indicate that pathological angiogenesis in the setting of tissue ischemia is impaired in SHR compared with WKY, and that this impairment can be reversed by ACE inhibition. The angiogenic properties of an ACE inhibitor may benefit patients with essential hypertension presenting with lower limb vascular insufficiency.

KEYWORDS ACE inhibitors; Angiogenesis; Capillaries; Collateral circulation; Hypertension; Ischemia


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Eur Heart J SupplHome page
J. S. Silvestre and B. I. Levy
Circulating progenitor cells and cardiovascular outcomes: latest evidence on angiotensin-converting enzyme inhibitors
Eur. Heart J. Suppl., August 1, 2009; 11(suppl_E): E17 - E21.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Bader
Kallikrein-Kinin System in Neovascularization
Arterioscler Thromb Vasc Biol, May 1, 2009; 29(5): 617 - 619.
[Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D. You, C. Cochain, C. Loinard, J. Vilar, B. Mees, M. Duriez, B. I. Levy, and J.-S. Silvestre
Combination of the Angiotensin-Converting Enzyme Inhibitor Perindopril and the Diuretic Indapamide Activate Postnatal Vasculogenesis in Spontaneously Hypertensive Rats
J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 766 - 773.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
D. You, C. Cochain, C. Loinard, J. Vilar, B. Mees, M. Duriez, B. I. Levy, and J.-S. Silvestre
Hypertension Impairs Postnatal Vasculogenesis: Role of Antihypertensive Agents
Hypertension, June 1, 2008; 51(6): 1537 - 1544.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
N. Nagai, Y. Oike, K. Izumi-Nagai, T. Koto, S. Satofuka, H. Shinoda, K. Noda, Y. Ozawa, M. Inoue, K. Tsubota, et al.
Suppression of Choroidal Neovascularization by Inhibiting Angiotensin-Converting Enzyme: Minimal Role of Bradykinin
Invest. Ophthalmol. Vis. Sci., May 1, 2007; 48(5): 2321 - 2326.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Donnini, R. Solito, A. Giachetti, H. J. Granger, M. Ziche, and L. Morbidelli
Fibroblast Growth Factor-2 Mediates Angiotensin-Converting Enzyme Inhibitor-Induced Angiogenesis in Coronary Endothelium
J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 515 - 522.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
J. Wysocki, M. Ye, M. J. Soler, S. B. Gurley, H. D. Xiao, K. E. Bernstein, T. M. Coffman, S. Chen, and D. Batlle
ACE and ACE2 Activity in Diabetic Mice.
Diabetes, July 1, 2006; 55(7): 2132 - 2139.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Srivastava, R. L. Terjung, and H. T. Yang
Basic fibroblast growth factor increases collateral blood flow in spontaneously hypertensive rats
Am J Physiol Heart Circ Physiol, August 7, 2003; 285(3): H1190 - H1197.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J.-M. Liu, F. Lawrence, M. Kovacevic, J. Bignon, E. Papadimitriou, J.-Y. Lallemand, P. Katsoris, P. Potier, Y. Fromes, and J. Wdzieczak-Bakala
The tetrapeptide AcSDKP, an inhibitor of primitive hematopoietic cell proliferation, induces angiogenesis in vitro and in vivo
Blood, April 15, 2003; 101(8): 3014 - 3020.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
T. Shimizu, H. Okamoto, S. Chiba, Y. Matsui, T. Sugawara, M. Akino, J. Nan, H. Kumamoto, H. Onozuka, T. Mikami, et al.
VEGF-mediated angiogenesis is impaired by angiotensin type 1 receptor blockade in cardiomyopathic hamster hearts
Cardiovasc Res, April 1, 2003; 58(1): 203 - 212.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
K. Amano, H. Matsubara, O. Iba, M. Okigaki, S. Fujiyama, T. Imada, H. Kojima, Y. Nozawa, S. Kawashima, M. Yokoyama, et al.
Enhancement of Ischemia-Induced Angiogenesis by eNOS Overexpression
Hypertension, January 1, 2003; 41(1): 156 - 162.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.